Jan 14, 2021 / 03:50PM GMT
Cory William Kasimov - JPMorgan Chase & Co, Research Division - Senior Biotechnology Analyst
All right. Good morning, everyone, from the virtual JPMorgan Healthcare Conference. My name is Cory Kasimov, and it's my pleasure to introduce our next company, Puma Biotechnology, and Chairman and CEO, Alan Auerbach. Please note there will not be a Q&A session following this presentation. So with that, Alan, thanks for being with us here today, and let me turn things over to you.
Alan H. Auerbach - Puma Biotechnology, Inc. - Founder, Chairman, President, CEO & Secretary
Great. Thank you very much, Cory. Are we moving to my slides now? So just a reminder, I'm going to be making forward-looking statements.
So on Slide 3, you can see our product pipeline with neratinib. As you can see, we have neratinib in many different indications, both marketed ones as well as ones in developments. In terms of marketed indications, the drug is approved in 2 indications, both in HER2-positive breast cancer. One is the extended adjuvant indication, where it's approved
Puma Biotechnology Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 14, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers